It is worth to mention that both CHX and tunicamycin have a smaller effect in MDA-MB-231 cells than in MCF10A cells, thus suggesting that Orai1 and STIM1 protein degradation is slower in MDA-MB-231 breast cancer cells (Supplementary Table S1). This evidence concerns the gene ORAI1 and breast carcinoma.